Showing results (161-170 of 219) with videos related to

Sort By:
Pageof 22
Oncoimmunology|April 11, 2018
Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapySimon Schliffke, Mariela Sivina, Ekaterina Kim, et al.
The Lancet. Haematology|December 4, 2018
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 studyElias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSteven E Coutré, Richard R Furman, Ian W Flinn, et al.
JCO Oncology Practice|November 18, 2024
Evaluation of the Impact of Monitoring for Tumor Lysis During Venetoclax Ramp-Up in Chronic Lymphocytic Leukemia in Routine Clinical PracticeNilanjan Ghosh, Ashley Matusz-Fisher, Rupali Bose, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2023
Genetic Predictors of Ibrutinib-related Cardiovascular Side Effects in Patients with Chronic Lymphocytic LeukemiaIssam S Hamadeh, Jai N Patel, Ryan Jacobs, et al.
The Lancet. Haematology|January 17, 2017
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trialPreetesh Jain, Michael Keating, Sarah Renner, et al.
Oncology and Therapy|June 22, 2026
Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLLDaniel A Ermann, Deborah M Stephens, Xiaoliang Wang, et al.
Ecology|April 1, 2018
Linking tree genetics and stream consumers: isotopic tracers elucidate controls on carbon and nitrogen assimilationZacchaeus G Compson, Bruce A Hungate, Thomas G Whitham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2022
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration CohortsPaul M Barr, Alessandra Tedeschi, William G Wierda, et al.
American Journal of Hematology|January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agentsElias Jabbour, Paolo Strati, Monica Cabrero, et al.
Pageof 22